In a recent phase II clinical trial, MOLTO, completed in February 2023, a combination therapy of atezolizumab, obinutuzumab and venetoclax demonstrated a significant improvement in response and survival rates for patients with Richter syndrome, specifically those with diffuse large B-cell lymphoma ( RS -DLBCL).
A median survival of 31.6 months ...